USRM
U.S. Stem Cell, Inc.Company Information
- Company Name
- U.S. Stem Cell, Inc.
- CIK
- CIK0001388319
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- USRM: OTC
- Fiscal Year End
- December 31
- Owner Organization
- Not Available
- SIC
- 8731
- SIC Description
- Services-Commercial Physical & Biological Research
- Ticker
- USRM
SEC filing data through
Insider Sentiment
- Last purchase
- 2017-08-17
- Last sale
- —
- Shares purchased (TTM)
- 2,999,614
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- —
- Institutional shares owned
- —
- Shares outstanding
- —
- Ownership
- —
Earnings Market Reaction
- Filing date
- 2023-04-14
- Price on filing date
- —
- 1-month reaction
- -16.67%
- 3-month reaction
- -30.56%
Balance Sheet
Values in millions ($)| Line item | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Accounts Receivable Net Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Assets Current | ||||||||||||||||||
| Assets Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | ||||||
| Inventory Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Prepaid Expense And Other Assets Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Investments | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | ||||||
| Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | ||||||
Liabilities And Stockholders Equity | ||||||||||||||||||
| Accounts Payable Current | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Accrued Liabilities Current | 3 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | ||||||
| Bank Overdrafts | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | ||||||
| Due To Related Parties Current | - | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Deferred Gain On Sale Of Property | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | ||||||
| Other Liabilities Current | 1 | - | - | - | 1 | - | - | - | - | - | - | - | ||||||
| Deferred Revenue Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 | ||||||
Liabilities Current | ||||||||||||||||||
| Deposit Liability Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Liabilities Current | 14 | 14 | 13 | 13 | 12 | 12 | 11 | 11 | 11 | 10 | 10 | 9 | ||||||
| Notes Payable Related Parties Classified Current | - | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 3 | 4 | 3 | 3 | ||||||
| Notes Payable | 4 | - | - | - | 3 | - | - | - | - | - | - | - | ||||||
| Long Term Debt And Capital Lease Obligations Current | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 1 | 1 | 1 | ||||||
| Notes Payable Current | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Convertible Notes Payable Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Liabilities Noncurrent | ||||||||||||||||||
| Liabilities Noncurrent | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Deferred Revenue Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Long Term Notes Payable | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Liabilities | 15 | 14 | 14 | 14 | 13 | 12 | 12 | 12 | 12 | 11 | 10 | 10 | ||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Stockholders Equity | -15 | -14 | -14 | -13 | -13 | -12 | -12 | -11 | -12 | -11 | -10 | -10 | ||||||
| Additional Paid In Capital | 127 | 127 | 127 | 127 | 127 | 126 | 126 | 126 | 124 | 124 | 124 | 124 | ||||||
| Retained Earnings Accumulated Deficit | -143 | -142 | -141 | -141 | -140 | -139 | -138 | -137 | -137 | -136 | -135 | -134 | ||||||
| Liabilities And Stockholders Equity | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | ||||||
| Allowance For Doubtful Accounts Receivable Current | 0 | 0 | 0 | 0 | 0 | 0 | - | - | 0 | - | - | - | ||||||
| Debt Instrument Unamortized Discount | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Debt Instrument Unamortized Discount Current | - | 0 | 0 | 0 | - | - | - | - | - | - | - | - | ||||||
| Debt Instrument Unamortized Discount Noncurrent | 0 | - | - | - | 0 | - | - | - | 0 | - | - | - | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 2,000 | 2,000 | 2,000 | 2,000 | 2,000 | 2,000 | 2,000 | 2,000 | 2,000 | 2,000 | 2,000 | 2,000 | ||||||
| Common Stock Shares Issued | 634 | 632 | 598 | 592 | 504 | 461 | 452 | 450 | 436 | 430 | 428 | 425 | ||||||
| Shares Outstanding | 634 | 632 | 598 | 592 | 504 | 461 | 452 | 450 | 436 | 430 | 428 | 425 | ||||||
Select a line item above to chart it.
Recent filings
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialU.S. Stem Cell, Inc. (USRM) — SEC Financial Statements & Analysis
U.S. Stem Cell, Inc. (USRM) is a services-commercial physical & biological research company, incorporated in FL. U.S. Stem Cell, Inc. trades on OTC as: USRM. U.S. Stem Cell, Inc. (USRM)'s most recent SEC filing is a Form 10-K for the period ended 2022-12-31, filed with the SEC on 2023-04-14. Based on its latest SEC filing (Form 10-Q, period ending 2022-12-31), U.S. Stem Cell, Inc. carries a market cap of $3.05M, a P/E ratio of -1.07x, a P/B ratio of -0.21x, a P/S ratio of 37.11x, an enterprise value of $11.99M, and an EV/EBITDA multiple of -6.97x. On profitability, it posts a gross margin of 71.03%, an operating margin of -2096.90%, a net margin of -3483.21%, a Return on Equity (ROE) of 20.78%, and a Return on Assets (ROA) of -4801.73%. Per share, it reports EPS of $-0.00, free cash flow per share of $-0.00, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -59.13% year-over-year, net income growth of -13.06% year-over-year, and EPS growth of -31.00% year-over-year. On the balance sheet, it maintains a current ratio of 0.00x, a quick ratio of 0.00x, working capital of $-14.01M, a debt-to-equity ratio of -1.00x, a debt ratio of 217.72, an interest coverage ratio of -2.49x, free cash flow of $-304.85K (TTM), and net debt of $8.94M. Figures sourced from SEC EDGAR.
- Market Cap
- $3.05M
- P/E TTM
- -1.07x
- EPS TTM
- $-0.00
- P/B TTM
- -0.21x
- ROE TTM
- 20.78%
- ROA TTM
- -4801.73%
- Debt To Equity
- -1.00x
- Free Cash Flow TTM
- $-304.85K
- Net Revenue TTM Growth 1Y
- -59.13%
Data as of 2022-12-31 · Source: SEC EDGAR
Frequently Asked Questions
What industry is U.S. Stem Cell, Inc. in?
U.S. Stem Cell, Inc. (USRM) operates in the Services-Commercial Physical & Biological Research industry.
What exchange does USRM trade on?
U.S. Stem Cell, Inc. (USRM) trades on the OTC.
Where is U.S. Stem Cell, Inc. incorporated?
U.S. Stem Cell, Inc. is incorporated in FL.
When was U.S. Stem Cell, Inc. (USRM)'s most recent SEC filing?
U.S. Stem Cell, Inc. (USRM)'s most recent SEC filing is a Form 10-K for the period ended 2022-12-31, filed with the SEC on 2023-04-14.
What is USRM's market cap?
U.S. Stem Cell, Inc. (USRM) has a market capitalization of $3.05M as of 2022-12-31.
What is USRM's EPS (earnings per share)?
U.S. Stem Cell, Inc. (USRM)'s trailing twelve month EPS is $-0.00 as of 2022-12-31.
What is USRM's ROE (return on equity)?
U.S. Stem Cell, Inc. (USRM)'s trailing twelve month Return on Equity (ROE) is 20.78% as of 2022-12-31.
What is USRM's ROA (return on assets)?
U.S. Stem Cell, Inc. (USRM)'s trailing twelve month Return on Assets (ROA) is -4801.73% as of 2022-12-31.
What is USRM's EV/EBITDA?
U.S. Stem Cell, Inc. (USRM)'s trailing twelve month EV/EBITDA is -6.97x as of 2022-12-31.